VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful end-of-Phase 2 interactions with FDA in MDD; Phase...
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously...
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs
Xenon Pharmaceuticals has announced a public offering of $300 million in shares just days after it unveiled mixed Phase II data for its major depressive disorder program.
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (œXenon), a neurology-focused biopharmaceutical company, today announced that it has...
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (œXenon), a neurology-focused biopharmaceutical company, today announced the pricing of its...
Xenon`s MDD med fails ph. 2, elevating seizure potential